logo

Stocks On Lower Track - Taking Cues From Overseas, Early Financial Declines
By: Midnight Trader   Monday, August 31, 2009 9:11 AM

Vote for next session
The next market session will close:

U.S. PRE-MARKET INDICATORS

-Dow Industrial futures down 62 points.

-S&P 500 futures down 7 points.

-Nasdaq 100 futures down 15 points.

-Nasdaq-100 Pre-Market Indicator down 8.31 at 1634.93.

GLOBAL SENTIMENT

Nikkei up 0.6%

Hang Seng down 0.8%

FTSE-100 up 1.1%

PRE-MARKET SECTOR WATCH

(-) Large cap tech: mostly lower

(-) Chip stocks: firmer

(+,-) Small cap stocks: mixed

(+) Drug stocks: mostly higher

(+,-) Software stocks: mixed

(+,-) Internet stocks: mixed

(-) Financial stocks: mostly lower

(-,+) Auto stocks: mixed

(-,+) Airline stocks: mixed

(+,-) Retail stocks: mixed

DOWNSIDE MOVERS

(-) TSRA (-8%) remains lower after reports late Friday said company lost ruling.

(-) INTC (-0.7%) lower despite analyst raising price target.

(-) MS (-3.1%) gets analyst downgrade.

(-) C (-3.1%) down as Barron's article suggests profit-taking in issue.

(-) AIG (-9.1%) down as Barron's says stock looks expensive.

(-) LDK (-0.2%) loses early upside after signing pact with Chinese city for PV power projects.

UPSIDE MOVERS

(+) MDCO (+9.5%) gains on data showing Angiomax reduces cardiac mortality.

(+) MESA (+24.6%) gaining amid reported challenge to Delta's dropped contract.

(+) BBI (+4.2%) sells Irish retailer.

(+) PACR (+10.6%) gets amended credit pact.

(+) JCI (+0.8%) gains after Barron's story says stock may gain on continued demand for energy-efficient cars.

(+) SVA (+10.9%) says H1N1 vaccine passes expert evaluation.

(+) CMCSA (-1%) gains after court rejects limit on market share for cable companies.

(+) ETFC (+3.1%) gains after Citadel scraps share sale.

(+) EXPD (+1.3%) gets favorable Barron's coverage.

(+) ATVI (+2.7%) gets favorable Barron's coverage.

(+) AZN (+1.1%) presents positive late results in coronary study PLATO.

(+) GME (+4.1%) gets analyst upgrade.

(+) BJS (+10%) sold to Baker Hughes.

(+) DCTH (+38.2%) gets FDA orphan drug status for Doxorubicin.

MARKET DIRECTION

Stock futures are pointing to a lower start after stock averages salvaged a slim weekly gain on Friday, the sixth advance out of the past seven weeks.

Volume is expected to be thin in the week leading up to the long Labor Day holiday weekend, which could exaggerate market moves.

Next Page >>12

(0)
No Comments
Post Comment
Name:  
Alert for new comments:
Your email:
Your Website:
Title:
Comments:
   
 
 
 
 
   
 

The above story is the opinion of the author only and it does not reflect iStockAnalyst opinion. Further, the author is not personally advising you regarding the suitability of the story for your investment needs. In no event iStockAnalyst will be liable for any loss or damage including without limitation, indirect or consequential loss or damage, or any loss or damage whatsoever arising from or arising out of, or in connection with the use of this information. Please consult your investment advisor before making any investment decision.
  
Advertisement
Popular Articles
Related Press Releases
Advertisement
Partner Center
Recent Articles by Midnight Trader



Subscribe to Email Alerts rss feed or RSS feeds rss feed for articles from more than 500 contributors, press releases, SEC filings and full text news from more than four thousand sources.
Fundamental data is provided by Zacks Investment Research, market data is provided by AlphaTrade. , and Commentary and Press Releases provided by Quotemedia